Abiopharma

🔍 Gimbel Lisa (Executive)

Company: PubMatic, Inc. (PUBM)

Report Date: 2026-08-15

Detailed Transactions and Holdings:

• Acquired 1,395 shares of Class A Common Stock (Direct)
  Date: 2026-08-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 15,956.00 | transaction_form_type: 4
• Acquired 772 shares of Class A Common Stock (Direct)
  Date: 2026-08-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 16,728.00 | transaction_form_type: 4
• Acquired 801 shares of Class A Common Stock (Direct)
  Date: 2026-08-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 17,529.00 | transaction_form_type: 4
• Acquired 794 shares of Class A Common Stock (Direct)
  Date: 2026-08-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 18,323.00 | transaction_form_type: 4
• Sold 1,396 shares of Class A Common Stock at $17.0397 per share (Direct)
  Date: 2026-05-18 | Code: S | equity_swap_involved: 0 | shares_owned_after: 16,927.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 1,395 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 5,580.00 | transaction_form_type: 4 | Footnotes: F3, F4, F5
• Sold 772 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 4,636.00 | transaction_form_type: 4 | Footnotes: F3, F6, F5
• Sold 801 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 8,013.00 | transaction_form_type: 4 | Footnotes: F3, F7, F5
• Sold 794 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 11,125.00 | transaction_form_type: 4 | Footnotes: F3, F8, F5

Footnotes:

• F1: The sales reported on this line represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction.
• F2: The price reported in Column 4 is a weighted average price. These shares were sold as part of a block trade for multiple security holders of the Issuer at prices ranging from $16.84 to $17.37, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein with regard to the block trade.
• F3: Each RSU represents a right to receive one share of the Issuer's Class A Common Stock at the time of vesting for no consideration.
• F4: The RSUs vest as to 1/4 of the total shares on August 15, 2024, and 1/16th of the total shares will vest quarterly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
• F5: RSUs do not expire; they either vest or are canceled prior to the vesting date.
• F6: The RSUs vest as to 1/16 of the total shares quarterly beginning on May 15, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
• F7: The RSUs vest as to 1/16 of the total shares quarterly beginning on May 15, 2025, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
• F8: The RSUs vest as to 1/16 of the total shares quarterly beginning on May 15, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.